M Azoulay
01.03.2011
Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland
Brändle M, Azoulay M, Greiner R. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. Int J Clin Pharmacol Ther 2011; 49:217-230.
01.03.2011Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland
01.03.2011Int J Clin Pharmacol Ther 2011; 49:217-230
Brändle Michael, Azoulay M, Greiner R -A
Weiter
01.04.2007
Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland
Brändle M, Azoulay M, Greiner R. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. International journal of clinical pharmacology and therapeutics 2007; 45:203-20.
01.04.2007Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland
01.04.2007International journal of clinical pharmacology and therapeutics 2007; 45:203-20
Brändle Michael, Azoulay M, Greiner R A
Weiter